Abstract:Introduction: The Asia-Pacific, multicenter, non-randomized APEC study previously reported that the efficacy and safety profiles of cetuximab every 2 weeks combined with first-line FOLFOX or FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer (mCRC) were similar to those reported in pivotal studies for either chemotherapy regimen plus weekly cetuximab (Cheng et al Ann Oncol 2013:24(S4);Abstract PD0028). This subgroup analysis of the APEC study investigated tumor response and progression-free survival (PFS) according to treatment in patients grouped by tumor EGFR expression status. Methods: Eligible patients received cetuximab administered every 2 weeks (day 1 of each cycle, 500 mg/m2) with, based on investigator's choice, either FOLFOX or FOLFIRI. Study treatment was continued until disease progression, the occurrence of unacceptable toxicity or withdrawal of consent. The primary endpoint was tumor response; assessed radiologically (RECIST 1.0) every 8 weeks, PFS was a secondary endpoint. EGFR expression was determined retrospectively by immunohistochemistry (IHC) using the Dako EGFR pharmDxtrade kit with a cutoff point of ≥5% of tumor cells exhibiting a staining intensity of at least 1+. Best overall objective response and PFS were determined according to treatment in patients grouped by whether tumors were EGFR detectable or EGFR undetectable. Results: Of the 289 patients in the intent to treat (ITT) population of the APEC study, tumor samples from 154 (53%) patients were available for EGFR IHC analysis, with the majority subsequently evaluable for EGFR expression status (147/154 [95%]). EGFR expression was detectable in 120 tumors (82%) and was undetectable in 27 tumors (18%) from the 147 evaluable patients. There were markedly more Caucasian (22/120 [18%] vs 0/27) and fewer Asian patients (97/120 [81%] vs 27/27 [100%]) in the EGFR detectable compared with the EGFR undetectable groups. Other baseline characteristics in these groups were comparable. Objective response rates (ORR, 58.8% vs 55.8%) and median PFS times (11.1 vs 11.1 months) were similar in the ITT compared with the EGFR evaluable populations, and also in the FOLFOX + cetuximab and FOLFIRI + cetuximab treatment groups in these populations (Table). In patients treated with FOLFOX + cetuximab, the ORR was 60.3% (47/78 patients) in the EGFR detectable group and 50.0% (8/16 patients) in the EGFR undetectable group. In patients treated with FOLFIRI + cetuximab, the ORR was 54.8% (23/42 patients) in the EGFR detectable group and 36.4% (4/11 patients) in the EGFR undetectable group. Median PFS times were generally comparable according to treatment in the EGFR detectable and EGFR undetectable groups (Table). Conclusion: In this retrospective subgroup analysis of APEC study patients, there were no major differences in ORRs and median PFS times between the subgroups of patients with EGFR detectable and EGFR undetectable tumors. Because of the small numbers of patients in some subgroups, no definite conclusions could be made with regard to EGFR expression as a clinically useful biomarker for the activity of chemotherapy plus cetuximab.

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line Folfox or Folfiri in Patients with Kras or All Ras Wild-Type Metastatic Colorectal Cancer: the Phase 2 Apec Study

Efficacy and Safety of Every-2-weeks Cetuximab Combined with FOLFOX or FOLFIRI As First-Line Therapy in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (mcrc): an Asia-Pacific Nonrandomized Phase II Study (APEC).

First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study

China Special Issue on Gastrointestinal Tumors‐cetuximab Retreatment Plus Camrelizumab and Liposomal Irinotecan in Patients with RAS Wild‐type Metastatic Colorectal Cancer: Cohort B of the Phase II CRACK Study

Final Analysis of the Phase 2 Apec Study: Overall Survival (os) Data and Biomarker Subanalyses for First-Line Folfox or Folfiri with Cetuximab (cet) Once Every 2 Weeks in Patients (pts) with Kras or Ras (kras and Nras, Exons 2-4) Wild-Type (wt) Metastatic Colorectal Cancer (Mcrc).

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (clime Study)

Cetuximab Every 2 Weeks with First-Line Chemotherapy in APEC Study Patients with Metastatic Colorectal Cancer Grouped According to EGFR Expression

FOLFOX/XELOX Plus Cetuximab Administered Weekly Versus Biweekly As a First-Line Treatment for Patients with KRAS/RAS Wild-Type Metastatic Colorectal Cancer: a Retro-Spective Study

149PD Association Between Early Tumour Shrinkage (ETS) and Outcomes in RAS-wild Type (WT) Patients (pts) with Metastatic Colorectal Cancer (mcrc) Receiving First-Line FOLFOX or FOLFIRI + Cetuximab Every Other Week in the APEC Study

Phase II APEC Trial: the Impact of Primary Tumor Side on Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients with RAS Wild‐type Metastatic Colorectal Cancer

Impact Of Primary Tumor Side On Outcomes Of Every-2-Weeks (Q2w) Cetuximab Plus First-Line Folfox Or Folfiri In Patients With Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) In The Phase 2 Apec Trial.

Impact of Primary Tumor Side (TS) on Outcomes of Once-Every-2-weeks (q2w) Cetuximab + First-Line (1L) FOLFOX or FOLFIRI in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) in the Phase 2 APEC Trial.

Biweekly Cetuximab Plus FOLFIRI/irinotecan As First/second-Line Chemotherapy for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: a Retrospective Analysis in Southwest Chinese Population

Phase II Study of Biweekly Cetuximab Plus Mfolfox6 or Mfolfiri As Second-Line Treatment for Metastatic Colorectal Cancer and Exploratory Analysis of Associations Between DNA Methylation Status and the Efficacy of the Anti-Egfr Antibody: T-CORE1201

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type …